Press Releases

Date Title
Toggle Summary vTv Therapeutics Announces Company will Pre-specify New Subgroup with the FDA and Report Phase 3 Part B Results in June
Subgroup of Mild Alzheimer’s Patients in Part A of Phase 3 STEADFAST Study Demonstrated Positive Benefit HIGH POINT, N.C. --(BUSINESS WIRE)--May 9, 2018-- vTv Therapeutics Inc. (Nasdaq:VTVT) today announced that based on post-hoc analyses of the data from Part A of the Company’s Phase 3 STEADFAST
View HTML
Toggle Summary vTv Therapeutics Announces Topline Results from the First STEADFAST Phase 3 Study Evaluating Azeliragon in People with Mild Alzheimer’s Disease
HIGH POINT, N.C. --(BUSINESS WIRE)--Apr. 9, 2018-- vTv Therapeutics, Inc.  (vTv) (Nasdaq:VTVT) today announced that results from Part A of the Company’s Phase 3 STEADFAST study of the investigational medication azeliragon in people with mild Alzheimer’s disease did not meet either co-primary
View HTML
Toggle Summary vTv Therapeutics Announces Completion of Phase 1b Study Evaluating TTP399 for the Treatment of Type 1 Diabetes
Simplici-T1 is an adaptive Phase 1b/2 study being conducted with support from JDRF HIGH POINT, N.C. --(BUSINESS WIRE)--Mar. 22, 2018-- vTv Therapeutics Inc. (Nasdaq: VTVT) today announced the completion of Phase 1b of Simplici-T1, an adaptive Phase 1b/2 study assessing the pharmacokinetics,
View HTML
Toggle Summary vTv Therapeutics Reports 2017 Fourth Quarter and Full Year Financial and Operational Results and Recent Highlights
HIGH POINT, N.C. --(BUSINESS WIRE)--Feb. 27, 2018-- vTv Therapeutics Inc. (Nasdaq:VTVT) today provided a corporate update and reported financial and operational results for the fourth quarter and full year that ended December 31, 2017 . “We made tremendous progress across the spectrum of our
View HTML
Toggle Summary vTv Therapeutics and Reneo Pharmaceuticals Enter Licensing Agreement for PPAR-Delta Program
HIGH POINT, N.C. --(BUSINESS WIRE)--Dec. 21, 2017-- vTv Therapeutics Inc. (Nasdaq:VTVT) today announced that vTv Therapeutics LLC has entered into a global licensing agreement with Reneo Pharmaceuticals , a privately-held biotechnology company focused on developing treatments for orphan diseases.
View HTML
Toggle Summary vTv Therapeutics Announces Licensing Agreement with Hangzhou Zhongmei Huadong Pharmaceutical Co. to Rights for vTv’s GLP-1r Agonist Diabetes Program in China and Other Pacific Rim Territories
HIGH POINT, N.C. --(BUSINESS WIRE)--Dec. 21, 2017-- vTv Therapeutics Inc. (Nasdaq:VTVT) today announced that vTv Therapeutics LLC has entered into a licensing agreement with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. (“Huadong Pharmaceutical”) , a wholly-owned subsidiary of Huadong Medicine
View HTML
Toggle Summary vTv to Host Key Opinion Leader Event to Discuss the Current State of Clinical Development in Alzheimer’s Disease
HIGH POINT, N.C. --(BUSINESS WIRE)--Nov. 13, 2017-- vTv Therapeutics Inc.  (Nasdaq:VTVT) today announced that the Company will host a key opinion leader (KOL) presentation and webcast focused on the current state of clinical development in Alzheimer’s disease in New York City on Thursday, November
View HTML
Toggle Summary vTv Therapeutics Initiates Phase 1b/2 Study Evaluating TTP399 for the Treatment of Type 1 Diabetes
As Part of Industry Partnership with JDRF HIGH POINT, N.C. --(BUSINESS WIRE)--Nov. 8, 2017-- vTv Therapeutics Inc.  (Nasdaq: VTVT) announced today the initiation of simplici-T1, an adaptive Phase1b/2 study assessing the pharmacokinetics, pharmacodynamics, safety, and tolerability of TTP399 in adult
View HTML
Toggle Summary vTv Therapeutics Reports Third Quarter 2017 Financial and Operational Results
HIGH POINT, N.C. --(BUSINESS WIRE)--Nov. 1, 2017-- vTv Therapeutics Inc. ( vTv Therapeutics ) (Nasdaq:VTVT) today provided a corporate update and reported financial and operational results for the third quarter ended September 30, 2017 . “We’ve made significant progress in the third quarter of 2017
View HTML
Toggle Summary vTv Therapeutics to Present on Azeliragon at the 10th Clinical Trials on Alzheimer’s Disease (CTAD)
-- Azeliragon is the only receptor for advanced glycation endproducts (RAGE) antagonist in clinical development for Alzheimer’s disease -- HIGH POINT, N.C. --(BUSINESS WIRE)--Oct. 30, 2017-- vTv Therapeutics Inc. (Nasdaq:VTVT), today announced that the Company will present three posters on clinical
View HTML